Bevacizumab-containing treatment for relapsed or refractory Wilms tumor-Reference-Cited by-同舟云学术

Bevacizumab-containing treatment for relapsed or refractory Wilms tumor

Published:2024-07-23 Issue:9 Volume:24 Page:837-843
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Al-Jilaihawi Sarah¹,Spreafico Filippo²,Mavinkurve-Groothuis Annelies³,Drost Jarno⁴⁵,Perotti Daniela⁶,Koenig Christa⁷,Brok Jesper⁸

Affiliation:

1. Department of Paediatric Oncology, Bristol Royal Hospital for Children, Bristol, UK

2. Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

3. Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

4. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

5. Oncode Institute, Utrecht, The Netherlands

6. Predictive Medicine: Molecular Bases of Genetic Risk and Genetic Testing Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

7. Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

8. Department of Pediatric Hematology and Oncology, Rigshospitalet, Copenhagen, Denmark

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2024.2381537

Reference32 articles.

1. Wilms tumour

2. Treatment of relapsed Wilms tumors: lessons learned

3. Advances in the clinical management of high‐risk Wilms tumors

4. Biology and treatment of renal tumours in childhood

5. Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting